Cellphire
Highly Engaged Employees
Highly Engaged EmployeesBlood & Organ Banks · Maryland, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9430 Ave Key West, Rockville, Maryland, ...Website
www.cellphire.comRevenue
$9.1 MillionIndustry
ZI Rank: 3
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
2
4
4
3
About Cellphire
Cellphire Therapeutics is dedicated to saving lives by developing innovative platelet therapeutics aimed at addressing controllable hemorrhage, a leading cause of preventable death. Their products, including the freeze-dried platelet-derived hemostat FPH and Cryopreserved Platelets CPP, are currently in Phase 2 clinical studies and aim to improve hemostatic efficacy for military and civilian patients. The company focuses on ensuring that effective therapies are available to clinicians, particularly in critical situations such as trauma and surgery. With a vision that no one should die from controllable hemorrhage, Cellphire is committed to revolutionizing bleeding treatment through advanced cellular therapies.Explore more
Cellphire Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellphire your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Cellphire had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cellphire has new funding data
Product Launch: Get notified when Cellphire launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cellphire
Check out if Cellphire is spiking on competitors!
Check if Cellphire has recently received funding, and reach out quickly before it becomes old news!
Cellphire, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Cellphire recently announced quarterly report
Recommended Actions
Find VP level buyers at Cellphire
Find more new buyers
Compare Similar Companies to Cellphire
Compare insights from companies similar to Cellphire, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellphire is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Cellphire is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Cellphire.
Cellphire financials insights
Gather financial insights about Cellphire, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$1M
2016
Other Financing Round
$1.3M
2017
Other Financing Round
$3M
2020
Debt
$350K
2021
Series A
$15M
Cellphire Tech Stack
A closer look at the technologies used by Cellphire
Most Recent Scoops
Left Company
Executive Move
Funding
Award
Award
Funding
Cellphire News & Media
Cellphire Therapeutics Announces CRYPTICS Phase 2/3 Clinical Study Stopped Early for Efficacy Following Pre-Planned Interim Analysis by Independent Data Monitoring Committee (IDMC)
ROCKVILLE, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Cellphire Therapeutics, Inc., a clinical stage biotechnology company developing next-generation platelet-derived therapies, today announced receipt of feedback from the (IDMC) on the pre-planned interim analysis of its CRYPTICS (Cryopreserved Platelet Trial for Control of Bleeding in Surgery) clinical study (NCT04709705). This study is evaluating the safety and efficacy of CLPH-511, Cellphire’s investigational cryopreserved platelet product (CPPCellphire Therapeutics CLPH-511 Fast Track Designation Granted
FDA has granted CLPH-511 Fast Track Designation for the treatment of acute hemorrhage as an alternative to conventional platelets when not available or in short supply FDA has granted CLPH-511 Fast Track Designation for the treatment of acute hemorrhage as an alternative to conventional platelets when not available or in short supplyCellphire Therapeutics Treats First Patient in Phase 2/3 Cryopreserved Platelets Clinical Trial
ROCKVILLE, Md., March 29, 2022 /PRNewswire/ -- Cellphire Therapeutics, Inc., a biotechnology company developing next-generation pooled allogeneic cellular therapeutics for application across multiple medical indications, announced today that the 1st patient has been treated in its Phase...Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients
ROCKVILLE, Md., May 27, 2021 /PRNewswire/ -- Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company's...
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cellphire
Sign Up For FreeTo access detailed company insights
Cellphire Therapeutics is dedicated to saving lives by developing innovative platelet therapeutics aimed at addressing controllable hemorrhage, a leading cause of preventable death. Their products, including the freeze-dried platelet-derived hemostat FPH and Cryopreserved Platelets CPP, are currently in Phase 2 clinical studies and aim to improve h... Read More
